A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma

Cancer Research

Volumn 66, Issue 18, 2006, Pages 8949-8953

  Xing, Deyin ^a,b   Orsulic, Sandra ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; MITOMYCIN C; MYC PROTEIN; PACLITAXEL; PLATINUM; PROTEIN P53; RAD51 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CENTROSOME; CHEMOSENSITIVITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA DAMAGE; EPITHELIUM CELL; GENE MUTATION; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; ONCOGENE; OVARY CARCINOMA; OVARY CELL CULTURE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BRCA1 PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DISEASE MODELS, ANIMAL; DNA DAMAGE; EPITHELIAL CELLS; FEMALE; GENES, BRCA1; GENES, MYC; GENES, P53; MICE; MICE, TRANSGENIC; OVARIAN NEOPLASMS; OVARY; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749482498     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1495     Document Type: Article

References (20)

1. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
2. Werness BA, Parvatiyar P, Ramus SJ, et al. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst 2000;92:1088-91.
3. Ramus SJ, Bobrow LG, Pharoah PD, et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999;25:91-6.
4. Schuyer M, Berns EM. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol 1999;155:143-52.
5. Orsulic S, Li Y, Soslow RA, et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002;1:53-62.
6. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999;22:37-43.
7. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
8. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
9. King D, Orsulic S. A genetically denned mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A 2005;102:6936-41.
10. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005;8:255-65.
11. Wang Q, Zhang H, Kajino K, Greene MI. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 1998;17:1939-48.
12. Pusapati RV, Rounbehler RJ, Hong S, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A 2006;103:1446-51.
13. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507.
14. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001;20:7514-23.
15. 2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-95.
16. Zhou C, Huang P, Liu J. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem Biophys Res Commun 2005;336:952-60.
17. Samouelian V, Maugard CM, Jolicoeur M, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53, and/or CDNK2A. Cancer Chemother Pharmacol 2004;54:497-504.
18. Holford J, Rogers P, Kelland LR. Ras mutation and platinum resistance in human ovarian carcinomas in vitro. Int J Cancer 1998;77:94-100.
19. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-68.
20. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005;5:388-93.